STCube, Inc., a biopharmaceutical company, develops medicines in South Korea. The company develops anti-cancer immunotherapeutic drugs and anti-viral drugs. It offers platform technologies, which include In vivo RNAi ICP target discovery platform for exploring material ICP target; glycosylation-specific antibody development platform for development of antibodies that mask glycosylation sites on target proteins; and ICP functional assay platform for development of various in vivo/in vitro analytical/experimental methods. The company’s product pipeline consists of various anti-cancer drugs, including anti PD-L1 Ab and anti PD-1 Ab in preclinical study, and anti STT-005 for solid tumor; anti STT-003 Ab in phase-1 for lung, head, and neck cancer; small molecule STT-011 inhibitor candidate development for pancreatic cancer; anti STT-012 Ab for breast and prostate cancer; and anti STT-013 Ab for solid tumor. The company was formerly known as Schem Co., Ltd. and changed its name to STCube, Inc. in April 2008. The company was founded in 1989 and is headquartered in Seoul, South Korea.
Name | Title | Since | Age |
|---|---|---|---|
| Hyunjin Jung | Chairman and Chief Executive Officer | - | - |
| Dongwook Lee | Director | - | - |